CHB


China Biotech Innovation ETF

Fund Summary

The Global X China Biotech Innovation ETF (CHB) seeks to invest in companies that are directly involved in China’s biotechnology industry.

Fund Objective

The Global X China Biotech Innovation ETF (CHB) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive China Biotech Innovation Index.

Why CHB?

High Growth Potential

CHB enables investors to access high growth potential through companies central to the development of biotechnology in China.

Targeted Exposure

CHB delivers targeted exposure to an emerging theme and industry.

ETF Efficiency

In a single trade, CHB delivers access to dozens of companies with high exposure to the biotech theme in China.

Fund Details As of 04/15/21

Key Facts

Ticker CHB
Inception Date 09/22/20
CUSIP 37954Y251
ISIN US37954Y2515
Bloomberg Index Ticker SOLCHB
Primary Exchange Nasdaq
Number of Holdings 31

Stats & Fees

Net Assets $5,915,752
Net Asset Value (NAV) $16.90
Shares Outstanding 350,000
Total Expense Ratio 0.67%

Distributions

30-Day SEC Yield -0.37%
Distribution Frequency Semi-Annually

Fund Prices As of 04/15/21

NAV $16.90 Daily Change $0.08 0.49%
Market Price $17.07 Daily Change $0.22 1.31%
30-Day Median Bid-Ask Spread 0.67%

Performance History

As of recent month & quarter-end (03/31/21)
Fund NAV Market Price Index
Year-to-Date -1.22% -0.79% -1.13%
1 Month -4.56% -5.03% -4.56%
3 Months -1.22% -0.79% -1.13%
Since Inception 6.89% 7.55% 7.21%
Year-to-Date -1.22% -0.79% -1.13%
1 Month -4.56% -5.03% -4.56%
3 Months -1.22% -0.79% -1.13%
Since Inception 6.89% 7.55% 7.21%

Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized return is the average return gained or lost by an investment each year over a given time period.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. High short-term performance of the Fund, when observed, is unusual and investors should not expect such performance to be repeated.

Fund Characteristics As of 04/15/21

Return on Equity 6.70%
Weighted Avg. Market Cap 7,173 M
2020 2021
Price-to-earnings 469.74 97.10
Price-to-book value 6.62 6.35

Source: AltaVista Research, LLC

Top Holdings As of 04/16/21

Net Assets (%) Ticker Name SEDOL Market Price ($) Shares Held Market Value ($)
10.30 2269 HK WUXI BIOLOGICS CAYMAN INC BL6B9P1 13.51 45,050 608,787.70
8.69 000661 C2 CHANGCHUN HIGH-A BD5CDB3 66.75 7,700 514,006.27
8.02 ZLAB ZAI LAB LTD-ADR BD9GVY0 164.29 2,886 474,140.94
7.84 300142 C2 WALVAX BIOTECHNOLOGY CO-A BD5CG36 7.71 60,100 463,502.07
7.49 BGNE BEIGENE LTD-ADR BYYWPW6 305.54 1,449 442,727.46
5.64 300601 C2 SHENZHEN KANGT-A BFY8HT2 19.75 16,871 333,170.01
4.70 300357 C2 ZHEJIANG WOLWO-A BFY8GY0 10.18 27,300 277,932.89
4.16 1177 HK SINO BIOPHARMACEUTICAL B00XSF9 1.04 236,900 245,743.41
3.93 300676 C2 BGI GENOMICS CO LTD-A BFY8H58 19.45 11,938 232,183.45
3.72 300009 C2 ANHUI ANKE BIO-A BD5C829 2.73 80,400 219,671.12
3.65 300725 C2 PHARMABLOCK SC-A BFY8HC5 25.51 8,455 215,674.03
3.62 603345 C1 FU JIAN ANJOY-A BMXWM11 36.24 5,900 213,813.54
3.48 002007 C2 HUALAN BIOLOGI-A BD5CL19 6.56 31,400 205,958.46
2.94 600201 C1 JINYU BIO-TECH-A BP3RBF4 3.11 55,900 173,644.27
2.59 002422 C2 SICHUAN KELUN-A BD5CL08 3.21 47,700 153,145.51
2.44 600161 C1 BEIJING TIAN-A BP3R9J4 5.56 25,957 144,268.57
2.40 002030 C2 DA AN GENE CO -A BD5CKW3 4.74 30,000 142,131.05
2.33 CBPO CHINA BIOLOGIC P BF0G7L2 118.00 1,167 137,706.00
2.11 1548 HK GENSCRIPT BIOTECH CORP BD9Q2J2 2.03 61,350 124,753.70
1.79 002252 C2 SHANGHAI RAAS -A BD5CPJ5 1.13 93,800 105,993.58
1.70 603127 C1 JOINN LABORATO-A BK94819 22.27 4,500 100,195.49
1.29 1530 HK 3SBIO INC BY9D3L9 0.90 85,100 76,448.11
0.88 002038 C2 BEIJING SL -A BD5CJD7 1.62 32,200 52,134.96
0.71 000078 C2 SHENZ NEPTUNUS-A BD5CBK8 0.50 83,900 41,678.89
0.71 1873 HK VIVA BIOTECH HOLDINGS BJBL0L5 0.87 47,900 41,673.88
0.69 000710 C2 BERRY GENOMICS CO LTD-A BFFJRH2 4.44 9,155 40,608.41
0.50 603387 C1 GETEIN BIOTECH INC-A BFB4S90 5.21 5,700 29,722.87
0.45 603363 C1 FUJIAN AONONG-A BF2DZF1 2.01 13,220 26,552.90
0.43 6855 HK ASCENTAGE PHARMA BK9PZW2 4.01 6,400 25,657.82
0.36 6826 HK SHANGHAI HAOHA-H BWZN1R1 7.85 2,700 21,197.05
0.26 002880 C2 SHENZHEN WEIGU-A BMTCVX0 6.84 2,200 15,057.61
0.22 CASH 0.86 14,974 12,863.51
Holdings are subject to change.


Investing involves risk, including the possible loss of principal. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles, or from economic or political instability in other nations. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Investments in securities in the Biotechnology and Health Care sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. Securities focusing on a single country and narrowly focused investments may be subject to higher volatility. CHB is non-diversified.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s shares typically do not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Carefully consider the Fund’s investment objectives, risks, and charges and expenses before investing. This and other information can be found in the Fund’s summary or full prospectuses. Please read the prospectus carefully before investing.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.